Comparison of Two Combination Treatments in Localized Pancreatic Cancer

<p><span data-sheets-value= "{"1":2,"2":"<p>This week, we'll discuss a study that compared two combination treatments for previously untreated patients with localized pancreatic cancer. Then, we'll explore whether a longer-established diagnosis of cancer is associated with higher risk of severe COVID-19 infection or death from the virus. Last, we'll review the FDA's recent approval of a CAR T-cell immunotherapy for patients with relapsed or refractory mantle cell lymphoma.<br></p><p><b>Coverage of stories discussed this week on ascopost.com:</b></p><p><a href=\"https://ascopost.com/news/july-2020/first-line-folfirinox-vs-gemcitabinenab-paclitaxel-for-localized-pancreatic-cancer/\">First-Line FOLFIRINOX vs Gemcitabine/Nab-paclitaxel for Localized Pancreatic Cancer</a></p><p><a href=\"https://ascopost.com/news/july-2020/are-patients-with-a-longer-established-diagnosis-of-cancer-at-higher-risk-for-more-severe-infection-or-death-from-covid-19/\">Are Patients With a Longer-Established Diagn...